Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 5.7% – Should You Sell?

by · The Cerbat Gem

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report)’s share price fell 5.7% during mid-day trading on Friday . The stock traded as low as $6.85 and last traded at $6.8530. Approximately 940,271 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 2,473,997 shares. The stock had previously closed at $7.27.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MRVI shares. Wells Fargo & Company raised their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. UBS Group increased their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. Wall Street Zen lowered Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.83.

Get Our Latest Research Report on Maravai LifeSciences

Maravai LifeSciences Trading Down 5.0%

The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98. The stock’s 50-day moving average is $6.94 and its two-hundred day moving average is $5.16. The company has a market cap of $1.79 billion, a P/E ratio of -13.27 and a beta of 0.60.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $51.44 million during the quarter, compared to analyst estimates of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. As a group, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Maravai LifeSciences

Several large investors have recently added to or reduced their stakes in MRVI. Renaissance Technologies LLC lifted its holdings in Maravai LifeSciences by 0.9% during the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock valued at $12,069,000 after purchasing an additional 39,600 shares in the last quarter. General American Investors Co. Inc. raised its position in shares of Maravai LifeSciences by 8.3% during the 1st quarter. General American Investors Co. Inc. now owns 1,716,193 shares of the company’s stock valued at $4,857,000 after purchasing an additional 130,877 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Maravai LifeSciences by 64.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after buying an additional 558,050 shares in the last quarter. Brummer Multi Strategy AB lifted its stake in shares of Maravai LifeSciences by 66.0% during the 1st quarter. Brummer Multi Strategy AB now owns 759,743 shares of the company’s stock valued at $2,150,000 after buying an additional 302,036 shares in the last quarter. Finally, Eversept Partners LP boosted its holdings in Maravai LifeSciences by 147.2% in the 4th quarter. Eversept Partners LP now owns 718,582 shares of the company’s stock worth $2,335,000 after buying an additional 427,909 shares during the period. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences, Inc (NASDAQ: MRVI) is a life sciences company that develops and supplies products and services used in biopharmaceutical research, drug development and manufacturing. Its offerings support the production and analysis of nucleic acids, including DNA and RNA used in applications such as messenger RNA therapeutics, vaccines, gene therapies and molecular diagnostics.

Through its nucleic acid production businesses, Maravai provides specialized enzymes, modified nucleotides, nucleoside triphosphates, oligonucleotides, capping products and related materials.

Featured Stories